#piper-sandler
Latest news and interesting information about piper-sandler.
What if High Interest Becomes a Big Problem?
Piper Sandler warns of a fiscal crisis due to rising interest rates. Analysis of Congress's possible actions and political hurdles.
Piper Sandler Reiterates Alphabet Overweight on AI
Piper Sandler reiterates Alphabet Overweight rating and $425 target after Google I/O AI product launches.
Piper Sandler Reiterates Boston Scientific Buy Rating
Piper Sandler reiterated an Overweight rating on Boston Scientific. Agent DCB drives growth; stock undervalued per Bond.az.
Piper Sandler Reiterates Overweight on Climb Bio
Piper Sandler reiterates Overweight on Climb Bio. IgAN opportunity and CLYM116 outlook.
Piper Sandler cuts e.l.f. Beauty target to $60
Piper Sandler cuts e.l.f. Beauty price target to $60 from $85, maintains Neutral rating. Stock trades at $53.23 near 52-week low.
Piper Sandler cuts Boot Barn target on guidance
Piper Sandler lowered Boot Barn price target to $226 from $230, maintaining Overweight. Q4 results beat, FY2027 guidance implies EPS growth up to 18%. Stock down 17% YTD.
Piper Sandler Raises Charles Schwab Target to $105
Piper Sandler raises Charles Schwab price target to $105. Analyst cites revenue guidance boost from investor day.
Piper Sandler Lowers Figma Target on Margin
Piper Sandler cuts Figma price target to $30 from $35 due to margin pressure, despite strong revenue growth of 46% in Q1.
Piper Sandler Raises Biogen Target to $225
Piper Sandler raises Biogen price target to $225 from $214. Phase II trial of BIIB080 missed primary endpoint but showed slowing of clinical decline at lowest dose.
Piper Sandler reiterates Boston Properties stock rating
Piper Sandler reaffirms Overweight rating on Boston Properties stock with $75 target. AI demand driving office market changes.
...